Immutep (IMMP) announces positive data from the EFTISARC-NEO Phase II trial were shared in a Proffered Paper oral presentation by Katarzyna Kozak, M.D., Ph.D., Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland, at the 2025 European Society of Medical Oncology, ESMO, Congress in Berlin, Germany. The investigator-initiated Phase II study evaluating eftilagimod alfa with radiotherapy plus KEYTRUDA in the neoadjuvant setting for resectable soft tissue sarcoma met the primary endpoint and significantly exceeded the study’s prespecified 35% tumour hyalinization/fibrosis. In the evaluable patient population, the novel combination with efti reached a median 51.5% tumour hyalinization/fibrosis.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMMP:
- Immutep Completes FDA Project Optimus, Advances Efti Trials
- Immutep announces completion of FDA Project Optimus requirements
- Citizens JMP healthcare analysts hold an analyst/industry conference call
- Promising Developments in Immutep’s Clinical Trials Drive Buy Rating
- Immutep announces update for TACTI-004 Phase III trial